Liver Fibrosis - Pipeline Review, H2 2015 Liver Fibrosis - Pipeline Review, H2 2015 market research report is the latest addition to RnRMarketResearch.com and its collection of Therapeutics business intelligence reports aimed to help take better decisions. This report provides comprehensive information on the therapeutic development for Liver Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Fibrosis and special features on latestage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on H2, 2015 Pipeline Review of “Liver Fibrosis� addition with 51 market data tables and 15 figures, spread across 182 pages is http://www.rnrmarketresearch.com/liver-fibrosis-pipeline-review-h2-2015-marketreport.html . This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources, put together by professional's team. Drug profiles/records featured in the report undergoes periodic updating following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Companies Discussed/Mentioned in this Research: Advinus Therapeutics Ltd., AiCuris GmbH & Co. KG, Angion Biomedica Corp., Bioneer Corporation, BiOrion Technologies B.V., Boehringer Ingelheim GmbH, Celgene Corporation, Dicerna Pharmaceuticals, Inc., Digna Biotech, S.L., Evotec AG, FibroGen, Inc., Galectin Therapeutics, Inc., Genfit SA, Gilead Sciences, Inc., GNI Group Ltd., HEC Pharm Co., Ltd., Intercept Pharmaceuticals, Inc., Isarna Therapeutics GmbH, KineMed, Inc., LG Life Science LTD., Nitto Denko Corporation, Pfizer Inc., Pharmaxis Limited, Promedior, Inc., Promethera
Biosciences S.A., ProMetic Life Sciences Inc., RuiYi Inc., RXi Pharmaceuticals Corporation, SciFluor Life Sciences, LLC, TCM Biotech International Corp, Vascular Biogenics Ltd., Virobay Inc. and XTuit Pharmaceuticals, Inc.
Drugs Profile Discussed in this Research: AIC-649, ANG-3281, ANG-4011, Antisense RNAi Oligonucleotide for Liver Fibrosis, BOT-162, CC-539, CC-90001, CIGB-500, CPI-43132, CT-140, DB-036, DCBBO-1202, disitertide, Drugs for Tissue Fibrosis, Drug to Inhibit Galectin-3 for Fibrosis, Drugs to Inhibit NADPH Oxidase for Influenza and Liver Fibrosis, elafibranor, F-351, FG-3019, GM-CT-01, m GRMD-02, HEC00000585, HepaStem, INT-767, ISTH-0047, KW-1, LC-280126, melittin, MOR-8457, NDL02s0201, noscapine, NPLC-0393, P-17, PBI-4050, PRM-151, PXS-4728A, PXS-5033A, Recombinant Enzyme to Replace MMP-9 for Liver Fibrosis and Pulmonary Fibrosis, RXI209, RYI-018, selonsertib, simtuzumab, Small Molecule for Liver Fibrosis, Small Molecule to Antagonize GPR91 for Retinal Angiogenesis and Liver Fibrosis, Small Molecules for Fibrosis, Small Molecules to Antagonize Receptor Tyrosine Kinase for Liver Fibrosis, Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis, Synthetic Peptide to Inhibit RSK for Fibrosis and Oncology, TCM-808FB, VB-201, VBY-376 and VBY-825 Inquire before buying for this report http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=440983 . (This is a premium report price at US$2000 for a single user PDF license)
Scope: •
The report provides a snapshot of the global therapeutic landscape of Liver Fibrosis
•
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
•
The report reviews key players involved in the therapeutics development for Liver Fibrosis and enlists all their major and minor projects
•
The report summarizes all the dormant and discontinued pipeline projects
•
A review of the Liver Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
•
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
•
A detailed assessment of monotherapy and combination therapy pipeline projects
•
Coverage of the Liver Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type
•
Latest news and deals relating related to pipeline products
Reasons to buy: •
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
•
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
•
Develop strategic initiatives by understanding the focus areas of leading companies
•
Identify and understand important and diverse types of therapeutics under development for Liver Fibrosis
•
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
•
Devise corrective measures for pipeline projects by understanding Liver Fibrosis pipeline depth and focus of Indication therapeutics
•
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
•
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Explore More Research Report on Therapeutics Market. Some of the common therapies that are popular among the people today include the acupressure, homeopathy, allopathy, naturopathy and many more. The different therapies not only allow overcoming the different diseases but also make it possible to prevent a wide range of diseases to occur. There is preventive medicine available today that can help to prevent a lot of diseases to occur to the human beings. The use of vaccines and the antibodies is one such example that fall under the scope of preventive medicine. Indeed, living a healthy life is very much possible today with the so much innovation in therapeutics.
About Us: RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.